Literature DB >> 32730861

Progesterone - Friend or foe?

Inger Sundström-Poromaa1, Erika Comasco2, Rachael Sumner3, Eileen Luders4.   

Abstract

Estradiol is the "prototypic" sex hormone of women. Yet, women have another sex hormone, which is often disregarded: Progesterone. The goal of this article is to provide a comprehensive review on progesterone, and its metabolite allopregnanolone, emphasizing three key areas: biological properties, main functions, and effects on mood in women. Recent years of intensive research on progesterone and allopregnanolone have paved the way for new treatment of postpartum depression. However, treatment for premenstrual syndrome and premenstrual dysphoric disorder as well as contraception that women can use without risking mental health problems are still needed. As far as progesterone is concerned, we might be dealing with a two-edged sword: while its metabolite allopregnanolone has been proven useful for treatment of PPD, it may trigger negative symptoms in women with PMS and PMDD. Overall, our current knowledge on the beneficial and harmful effects of progesterone is limited and further research is imperative.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allopregnanolone; Emotion; Hormonal contraceptives; Postpartum depression; Premenstrual dysphoric disorder; Progesterone

Mesh:

Substances:

Year:  2020        PMID: 32730861     DOI: 10.1016/j.yfrne.2020.100856

Source DB:  PubMed          Journal:  Front Neuroendocrinol        ISSN: 0091-3022            Impact factor:   8.606


  8 in total

1.  Characterization of Depressive Symptom Trajectories in Women between Childbirth and Diagnosis.

Authors:  Natalia Chechko; Susanne Stickel; Elena Losse; Aliaksandra Shymanskaya; Ute Habel
Journal:  J Pers Med       Date:  2022-03-28

2.  Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator.

Authors:  Erika Comasco; Inger Sundström-Poromaa; Elisavet Kaltsouni; Patrick M Fisher; Manon Dubol; Steinar Hustad; Rupert Lanzenberger; Vibe G Frokjaer; Johan Wikström
Journal:  Neuropsychopharmacology       Date:  2021-04-29       Impact factor: 7.853

Review 3.  Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome.

Authors:  Lara Tiranini; Rossella E Nappi
Journal:  Fac Rev       Date:  2022-04-28

4.  Association Between Hormonal Birth Control, Substance Use, and Depression.

Authors:  Sharlene D Newman
Journal:  Front Psychiatry       Date:  2022-02-08       Impact factor: 4.157

Review 5.  Psychiatric Symptoms Across the Menstrual Cycle in Adult Women: A Comprehensive Review.

Authors:  Ariel B Handy; Shelly F Greenfield; Kimberly A Yonkers; Laura A Payne
Journal:  Harv Rev Psychiatry       Date:  2022 Mar-Apr 01       Impact factor: 3.732

Review 6.  Progesterone: A Steroid with Wide Range of Effects in Physiology as Well as Human Medicine.

Authors:  Lucie Kolatorova; Jana Vitku; Josef Suchopar; Martin Hill; Antonin Parizek
Journal:  Int J Mol Sci       Date:  2022-07-20       Impact factor: 6.208

7.  Development of Vaginal Carriers Based on Chitosan-Grafted-PNIPAAm for Progesterone Administration.

Authors:  Oana-Teodora Afloarea; Catalina Natalia Cheaburu Yilmaz; Liliana Verestiuc; Nela Bibire
Journal:  Gels       Date:  2022-09-17

8.  Effects of exogenous melatonin on sleep and circadian rhythms in women with premenstrual dysphoric disorder.

Authors:  Christophe Moderie; Philippe Boudreau; Ari Shechter; Paul Lespérance; Diane B Boivin
Journal:  Sleep       Date:  2021-12-10       Impact factor: 6.313

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.